Articles related to CLINICAL TRIALS

In the confirmatory trial, Clarity AD, of 1,795 patients with early AD, findings showed a reduction of dementia scoring of 27% vs. placebo. These findings were seen as early as 6 months.

In the 5-year, multi-center, randomized, controlled GRADE trial (Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study), insulin glargine and liraglutide were about 13% more effective than glimepiride in keeping HbA1c lower than 7.0%, and 30% more effective than sitagliptin.

In the phase III trial for zuranolone, 67.4% of patients who received an initial 2-week course at the 30-mg dose level initially achieved a 50% or greater reduction from baseline on the HAMD-17. Over the following year, half of those patients required additional 2-week courses of therapy. Of the group who received the 50-mg dose, only 25% needed subsequent courses.

In patients with stage IIIB-D or IV melanoma, adjuvant nivolumab with ipilimumab did not increase recurrence-free survival compared to nivolumab monotherapy. Both treatment regimens’ safety and health-related quality of life were similar with earlier research.

A response to “practice-changing data” in the first- and second-line setting The American Society of Clinical Oncology (ASCO) has amended its advice against routinely administering PARP inhibitor monotherapy to patients with recurrent platinum-sensitive epithelial ovarian cancer in the second or later-line situation.

This update is based on the results from the June 2022 ATHENA-MONO2 phase III multinational, double-blind, randomized controlled trial (RCT), which showed a significant improvement in progression-free survival (PFS) in patients with stage III-IV epithelial ovarian cancer (EOC) who are in complete or partial response to first-line platinum-based chemotherapy.